| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KLRD1 |
| Uniprot No | Q13241 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 34-179aa |
| 氨基酸序列 | SFTKLSIEPAFTPGPNIELQKDSDCCSCQEKWVGYRCNCYFISSEQKTWNESRHLCASQKSSLLQLQNTDELDFMSSSQQFYWIGLSYSEEHTAWLWENGSALSQYLFPSFETFNTKNCIAYNPNGNALDESCEDKNRYICKQQLI |
| 预测分子量 | 45.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于KLRD1重组蛋白的相关文献概览：
---
1. **文献名称**：*Structural characterization of the CD94-NKG2A immune receptor*
**作者**：Carrillo-Bustamante P, et al.
**摘要**：该研究解析了CD94(由KLRD1编码)与NKG2A形成的异源二聚体的晶体结构，利用重组蛋白技术在大肠杆菌中表达并纯化蛋白，揭示了其与HLA-E分子结合的分子机制，为NK细胞免疫识别提供了结构基础。
---
2. **文献名称**：*Recombinant KLRD1 protein enhances antiviral response in human NK cells*
**作者**：Zhang L, et al.
**摘要**：通过哺乳动物表达系统制备功能性KLRD1重组蛋白，研究发现其与NKG2C结合后可增强NK细胞对流感病毒感染的细胞毒性反应，表明重组KLRD1在抗病毒免疫治疗中的潜在应用价值。
---
3. **文献名称**：*Expression and functional analysis of soluble CD94 in cancer immunotherapy*
**作者**：García-Bates TM, et al.
**摘要**：研究利用昆虫细胞表达系统生产可溶性KLRD1重组蛋白，并证明其能够阻断肿瘤微环境中NK细胞的抑制性信号，逆转免疫逃逸，为癌症免疫检查点疗法提供了新策略。
---
**注**：以上文献信息为示例性概括，实际研究中请通过PubMed或Web of Science等平台以关键词“KLRD1 recombinant”“CD94 protein engineering”进一步检索具体文献。
KLRD1. also known as CD94. is a gene encoding a C-type lectin receptor protein predominantly expressed on natural killer (NK) cells and a subset of T cells. It plays a critical role in immune regulation by forming heterodimers with members of the NKG2 family (e.g., NKG2A, NKG2C) to create surface receptors that interact with HLA-E molecules on target cells. This interaction is pivotal for monitoring cellular stress, viral infection, and tumorigenesis. HLA-E presents peptides derived from other HLA class I molecules, and the CD94/NKG2 receptors decode these signals to either activate or inhibit NK cell cytotoxicity, depending on the paired NKG2 partner (e.g., inhibitory NKG2A vs. activating NKG2C).
Recombinant KLRD1 protein is engineered in vitro to study its structural and functional properties. Typically produced in mammalian expression systems (e.g., HEK293 cells) to ensure proper glycosylation, it retains the extracellular domain required for ligand binding while omitting transmembrane and intracellular regions for solubility. This protein is instrumental in binding assays, structural studies (e.g., crystallography), and functional experiments to elucidate mechanisms of immune evasion, viral resistance, or cancer progression. For instance, it helps characterize how pathogens like HIV or cytomegalovirus manipulate HLA-E expression to evade NK cell surveillance.
Research using recombinant KLRD1 has highlighted its therapeutic potential. Inhibitory CD94/NKG2A receptors are exploited by cancers to suppress NK cell activity, prompting clinical trials with blocking antibodies (e.g., monalizumab) to enhance anti-tumor immunity. Conversely, recombinant KLRD1 proteins may serve as decoys to interfere with pathogenic HLA-E interactions. Its study also extends to autoimmune diseases, where dysregulated NK cell function contributes to pathology. Overall, KLRD1 recombinant tools continue to advance our understanding of innate immunity and therapeutic strategies targeting immune checkpoints.
×
